DK3860990T3 - Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer - Google Patents
Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer Download PDFInfo
- Publication number
- DK3860990T3 DK3860990T3 DK19782584.7T DK19782584T DK3860990T3 DK 3860990 T3 DK3860990 T3 DK 3860990T3 DK 19782584 T DK19782584 T DK 19782584T DK 3860990 T3 DK3860990 T3 DK 3860990T3
- Authority
- DK
- Denmark
- Prior art keywords
- yap
- taz
- inhibitors
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Testing Relating To Insulation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306294.2A EP3632908A1 (en) | 2018-10-02 | 2018-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| PCT/EP2019/076681 WO2020070181A1 (en) | 2018-10-02 | 2019-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3860990T3 true DK3860990T3 (da) | 2022-12-19 |
Family
ID=63857833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19782584.7T DK3860990T3 (da) | 2018-10-02 | 2019-10-02 | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11999758B2 (da) |
| EP (2) | EP3632908A1 (da) |
| JP (1) | JP7430715B2 (da) |
| KR (1) | KR102693917B1 (da) |
| CN (1) | CN113039182B (da) |
| AU (1) | AU2019352009B2 (da) |
| BR (1) | BR112021006229A2 (da) |
| CA (1) | CA3114375A1 (da) |
| DK (1) | DK3860990T3 (da) |
| ES (1) | ES2931150T3 (da) |
| HU (1) | HUE059965T2 (da) |
| IL (1) | IL281999B2 (da) |
| MX (1) | MX2021003843A (da) |
| PL (1) | PL3860990T3 (da) |
| PT (1) | PT3860990T (da) |
| SI (1) | SI3860990T1 (da) |
| UA (1) | UA128980C2 (da) |
| WO (1) | WO2020070181A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| CA3194456A1 (en) | 2020-09-30 | 2022-04-07 | Arnaud Marchand | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| AR125350A1 (es) | 2021-04-16 | 2023-07-12 | Orion Corp | Inhibidores tead |
| WO2023042901A1 (ja) * | 2021-09-16 | 2023-03-23 | 慶應義塾 | 小細胞肺癌患者ｃｔｃ由来オルガノイド製造と小細胞肺癌分子標的治療薬としてのｉｇｆ１ｒ阻害剤 |
| EP4452253A2 (en) | 2021-12-23 | 2024-10-30 | The Katholieke Universiteit Leuven | 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead |
| TW202423428A (zh) | 2022-09-29 | 2024-06-16 | 香港商英矽智能科技知識產權有限公司 | Tead抑制劑及其使用方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN116239498B (zh) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | 制备克立硼罗中间体的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5306818A (en) | 1990-11-01 | 1994-04-26 | Sterling Winthrop Inc. | Tetrahydro 2-saccharinylmerthyl aryl carboxylates |
| US6200957B1 (en) | 1995-12-14 | 2001-03-13 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6011034A (en) | 1998-02-12 | 2000-01-04 | Uniroyal Chemical Company, Inc. | Insecticidal dihydrooxadiazine compounds |
| AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| AU2006295397A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP2170815A2 (en) | 2007-06-20 | 2010-04-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| WO2009062258A1 (en) | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
| JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| FR2942797B1 (fr) | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| PH12013501126A1 (en) | 2010-12-21 | 2022-03-30 | Janssen Pharmaceutica Nv | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| JP6206926B2 (ja) | 2011-11-23 | 2017-10-04 | キャンサー・リサーチ・テクノロジー・リミテッド | 異常なプロテインキナーゼｃのチエノピリミジン阻害剤 |
| WO2013123071A1 (en) | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| EP2861570B1 (en) | 2012-06-19 | 2018-07-18 | Rutgers, The State University of New Jersey | Antibacterial agents: aryl myxopyronin derivatives |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| TW201512173A (zh) | 2013-08-22 | 2015-04-01 | Hoffmann La Roche | 炔基醇及其使用方法 |
| EP3086644A1 (en) * | 2013-12-23 | 2016-11-02 | Syngenta Participations AG | Benzoxaborole fungicides |
| UA122061C2 (uk) | 2014-10-08 | 2020-09-10 | Ф. Хоффманн-Ля Рош Аг | Похідні спіродіаміну як інгібітори альдостеронсинтази |
| EP3954685A1 (en) | 2014-12-29 | 2022-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| US10696642B2 (en) * | 2015-09-23 | 2020-06-30 | The General Hospital Corporation | TEAD transcription factor autopalmitoylation inhibitors |
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| WO2017133517A1 (zh) | 2016-02-03 | 2017-08-10 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN109912609A (zh) * | 2017-12-12 | 2019-06-21 | 江苏三月光电科技有限公司 | 一种以含氮五元杂环为母核的化合物及其在有机电致发光器件上的应用 |
-
2018
- 2018-10-02 EP EP18306294.2A patent/EP3632908A1/en not_active Withdrawn
-
2019
- 2019-10-02 KR KR1020217011255A patent/KR102693917B1/ko active Active
- 2019-10-02 SI SI201930344T patent/SI3860990T1/sl unknown
- 2019-10-02 EP EP19782584.7A patent/EP3860990B1/en active Active
- 2019-10-02 HU HUE19782584A patent/HUE059965T2/hu unknown
- 2019-10-02 JP JP2021518089A patent/JP7430715B2/ja active Active
- 2019-10-02 US US17/278,429 patent/US11999758B2/en active Active
- 2019-10-02 UA UAA202101719A patent/UA128980C2/uk unknown
- 2019-10-02 IL IL281999A patent/IL281999B2/en unknown
- 2019-10-02 MX MX2021003843A patent/MX2021003843A/es unknown
- 2019-10-02 CA CA3114375A patent/CA3114375A1/en active Pending
- 2019-10-02 CN CN201980075645.2A patent/CN113039182B/zh active Active
- 2019-10-02 BR BR112021006229A patent/BR112021006229A2/pt not_active IP Right Cessation
- 2019-10-02 ES ES19782584T patent/ES2931150T3/es active Active
- 2019-10-02 PT PT197825847T patent/PT3860990T/pt unknown
- 2019-10-02 DK DK19782584.7T patent/DK3860990T3/da active
- 2019-10-02 AU AU2019352009A patent/AU2019352009B2/en active Active
- 2019-10-02 PL PL19782584.7T patent/PL3860990T3/pl unknown
- 2019-10-02 WO PCT/EP2019/076681 patent/WO2020070181A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US11999758B2 (en) | 2024-06-04 |
| MX2021003843A (es) | 2021-05-27 |
| BR112021006229A2 (pt) | 2021-07-06 |
| CN113039182B (zh) | 2024-02-20 |
| SI3860990T1 (sl) | 2022-11-30 |
| EP3860990B1 (en) | 2022-09-14 |
| JP7430715B2 (ja) | 2024-02-13 |
| EP3860990A1 (en) | 2021-08-11 |
| HUE059965T2 (hu) | 2023-01-28 |
| CA3114375A1 (en) | 2020-04-09 |
| UA128980C2 (uk) | 2024-12-18 |
| KR102693917B1 (ko) | 2024-08-09 |
| PT3860990T (pt) | 2022-10-18 |
| AU2019352009A1 (en) | 2021-04-15 |
| PL3860990T3 (pl) | 2023-01-23 |
| IL281999B1 (en) | 2023-11-01 |
| CN113039182A (zh) | 2021-06-25 |
| IL281999A (en) | 2021-05-31 |
| KR20210072001A (ko) | 2021-06-16 |
| ES2931150T3 (es) | 2022-12-27 |
| JP2022504077A (ja) | 2022-01-13 |
| EP3632908A1 (en) | 2020-04-08 |
| IL281999B2 (en) | 2024-03-01 |
| US20210323982A1 (en) | 2021-10-21 |
| WO2020070181A1 (en) | 2020-04-09 |
| AU2019352009B2 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3860990T3 (da) | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| HK1259388A1 (zh) | Yap/taz-tead互相作用的新化合物抑制劑及其在治療惡性間皮瘤中的用途 | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3331900T3 (da) | Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
| DK3733187T3 (da) | Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK4010329T3 (da) | Deutererede forbindelser til anvendelse ved behandling af cancer | |
| DK3256218T3 (da) | Kdm1a-hæmmer og anvendelse deraf i terapi | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3939658T3 (da) | Substitueret benzopyrrol og strukturelt relaterede komplementinhibitorer | |
| DK3753937T3 (da) | Atr-hæmmer og anvendelse deraf | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3601296T3 (da) | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3416945T3 (da) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
| DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer |